List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4156409/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection. New England Journal of Medicine, 2013, 369, 1807-1818.	27.0	697
2	Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet, The, 2009, 374, 796-806.	13.7	621
3	Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet, The, 2013, 381, 735-743.	13.7	455
4	Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 39-48.	2.1	211
5	Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 77-85.	2.1	198
6	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 515-519.	2.1	190
7	Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. Aids, 2010, 24, 1697-1707.	2.2	174
8	Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infectious Diseases, The, 2012, 12, 27-35.	9.1	160
9	Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEATOO1/ANRS143 randomised non-inferiority trial. Lancet, The, 2014, 384, 1942-1951.	13.7	158
10	The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology, 2009, 6, 27.	2.0	142
11	Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. Aids, 2008, 22, F1-F9.	2.2	133
12	Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infectious Diseases, The, 2015, 15, 785-792.	9.1	131
13	Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 139-147.	2.1	127
14	Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infectious Diseases, The, 2015, 15, 775-784.	9.1	122
15	Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 147-152.	2.1	110
16	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV,the, 2018, 5, e211-e220.	4.7	108
17	Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 411-418.	2.9	105
18	Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. Aids, 2012, 26, 2315-2326.	2.2	104

#	Article	IF	CITATIONS
19	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Lancet HIV.the, 2017, 4, e536-e546.	4.7	101
20	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV,the, 2018, 5, e23-e34.	4.7	83
21	Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV,the, 2015, 2, e464-e473.	4.7	69
22	A randomized study comparing instruments for measuring health-related quality of life in _HIV-infected patients. Aids, 1999, 13, 1727-1735.	2.2	64
23	Increasing Incidence of Hepatocellular Carcinoma in HIV-Infected Patients in Spain. Clinical Infectious Diseases, 2013, 56, 143-150.	5.8	62
24	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004–2013. Journal of Infection, 2016, 72, 587-596.	3.3	60
25	Low-Level HIV Viremia Is Associated With Microbial Translocation and Inflammation. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 129-134.	2.1	58
26	Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). Journal of Antimicrobial Chemotherapy, 2017, 72, 246-253.	3.0	57
27	Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. Aids, 2000, 14, 727-732.	2.2	53
28	Decrease in Serial Prevalence of Coinfection with Hepatitis C Virus among HIVâ€Infected Patients in Spain, 1997–2006. Clinical Infectious Diseases, 2009, 48, 1467-1470.	5.8	52
29	Functional status determined by Barthel Index predicts community acquired pneumonia mortality in general population. Journal of Infection, 2010, 61, 458-464.	3.3	52
30	Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antiviral Therapy, 2009, 14, 195-201.	1.0	51
31	The future of antiretroviral therapy: challenges and needs. Journal of Antimicrobial Chemotherapy, 2010, 65, 827-835.	3.0	46
32	Anal Human Papillomavirus Genotype Distribution in HIV-Infected Men Who Have Sex with Men by Geographical Origin, Age, and Cytological Status in a Spanish Cohort. Journal of Clinical Microbiology, 2013, 51, 3512-3520.	3.9	46
33	Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men. Aids, 2016, 30, 37-44.	2.2	46
34	Evaluating changes in health status in HIV-infected patients: Medical Outcomes Study-HIV and Multidimensional Quality of Life-HIV quality of life questionnaires. Aids, 2000, 14, 1439-1447.	2.2	45
35	Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions. BMC Cancer, 2018, 18, 112.	2.6	43
36	Risk factors for sexual and erectile dysfunction in HIV-infected men: the role of protease inhibitors. Aids, 2010, 24, 255-264.	2.2	42

#	Article	IF	CITATIONS
37	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. Lancet HIV,the, 2020, 7, e565-e573.	4.7	42
38	Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-NaÃ <sup>-</sup> ve HIV-Infected Patients (CoRIS) Are Due to Recombinant Viruses. Journal of Clinical Microbiology, 2012, 50, 407-413.	3.9	41
39	Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. Aids, 2012, 26, 2241-2246.	2.2	37
40	The Determination of Total Testosterone and Free Testosterone (RIA) are not Applicable to the Evaluation of Gonadal Function in HIV-Infected Males. Journal of Sexual Medicine, 2010, 7, 2873-2883.	0.6	35
41	Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. Journal of Antimicrobial Chemotherapy, 2012, 67, 2020-2028.	3.0	35
42	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. Open Forum Infectious Diseases, 2016, 3, ofw059.	0.9	34
43	Fluconazole plus allopurinol in treatment of visceral leishmanlasis. Journal of Antimicrobial Chemotherapy, 1996, 37, 1042-1043.	3.0	33
44	What Drives the Number of High-Risk Human Papillomavirus Types in the Anal Canal in HIV-Positive Men Who Have Sex With Men?. Journal of Infectious Diseases, 2013, 207, 1235-1241.	4.0	33
45	Avascular necrosis of the bone in HIV-infected patients: incidence and associated factors. Aids, 2002, 16, 481-483.	2.2	31
46	Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-NaÃ⁻ve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK. HIV Clinical Trials, 2012, 13, 228-232.	2.0	30
47	Clinical Utility of Maraviroc. Clinical Drug Investigation, 2011, 31, 527-542.	2.2	29
48	Anal squamous intraepithelial lesions are frequent among young HIVâ€infected men who have sex with men followed up at the Spanish AIDS Research Network Cohort (CoRISâ€HPV). International Journal of Cancer, 2013, 133, 1164-1172.	5.1	27
49	Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa®), in antiretroviral-naÃ`ve patients: A 48-week, multicentre, randomized study (Lake Study). Antiviral Research, 2010, 85, 403-408.	4.1	26
50	Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. Aids, 2011, 25, 761-766.	2.2	26
51	Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial. Clinical Infectious Diseases, 2015, 60, 811-820.	5.8	26
52	Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. HIV Medicine, 2014, 15, 330-338.	2.2	25
53	Adherence, Quality of Life, and General Satisfaction with Co-formulated Zidovudine, Lamivudine, and Abacavir on Antiretroviral-Experienced Patients. HIV Clinical Trials, 2004, 5, 33-39.	2.0	23
54	The effects of Maraviroc on liver fibrosis in HIV/HCV coâ€infected patients. Journal of the International AIDS Society, 2014, 17, 19643.	3.0	23

#	Article	IF	CITATIONS
55	Shorter Telomere Length Predicts Poorer Immunological Recovery in Virologically Suppressed HIV-1–Infected Patients Treated With Combined Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 21-29.	2.1	23
56	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1056-1062.	3.0	22
57	Progressive Multifocal Leukoencephalopathy Treated with Cidofovir in HIV-infected Patients Receiving Highly Active Anti-retroviral Therapy. Journal of Infection, 2000, 41, 182-184.	3.3	21
58	Relapsing Cutaneous Alternariosis in a Kidney Transplant Recipient Cured with Liposomal Amphotericin B. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 51-53.	2.9	21
59	Pruritus in HIV-infected patients in the era of combination antiretroviral therapy: a study of its prevalence and causes. International Journal of STD and AIDS, 2012, 23, 255-257.	1.1	21
60	COVIDâ€19 in hospitalized HIVâ€positive and HIVâ€negative patients: A matched study. HIV Medicine, 2021, 22, 867-876.	2.2	21
61	Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naÃ <sup>-</sup> ve HIV-infected patients (CoRIS). Antiviral Research, 2011, 89, 19-25.	4.1	20
62	Relationship between plasma bilirubin level and oxidative stress markers in <scp>HIV</scp> â€infected patients on atazanavir― <i>vs</i> . efavirenzâ€based antiretroviral therapy. HIV Medicine, 2016, 17, 653-661.	2.2	20
63	Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. European Journal of Clinical Pharmacology, 2007, 63, 669-675.	1.9	19
64	Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. Journal of Antimicrobial Chemotherapy, 2011, 66, 1346-1350.	3.0	19
65	Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004–2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. PLoS ONE, 2014, 9, e116226.	2.5	19
66	Doravirine dose Selection and 96-Week Safety and Efficacy versus Efavirenz in Antiretroviral Therapy-Naive Adults with HIV-1 Infection in a Phase IIb Trial. Antiviral Therapy, 2019, 24, 425-435.	1.0	19
67	Acalculous Cholecystitis Associated with Plasmodium falciparum Malaria. Clinical Infectious Diseases, 2000, 31, 622-623.	5.8	18
68	High Irisin levels in nondiabetic <scp>HIV</scp> â€infected males are associated with insulin resistance, nonalcoholic fatty liver disease, and subclinical atherosclerosis. Clinical Endocrinology, 2018, 89, 414-423.	2.4	18
69	Neurocognitive Impairment in Well-Controlled HIV-Infected Patients: A Cross-Sectional Study. AIDS Research and Human Retroviruses, 2019, 35, 634-641.	1.1	18
70	Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. Journal of Antimicrobial Chemotherapy, 2008, 63, 178-183.	3.0	15
71	Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions. HIV Medicine, 2010, 11, 545-553.	2.2	15
72	Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 2083-2088.	2.9	15

#	Article	IF	CITATIONS
73	Vitamin D insufficiency and subclinical atherosclerosis in nonâ€diabetic males living with HIV. Journal of the International AIDS Society, 2014, 17, 18945.	3.0	15
74	Subclinical atherosclerosis in low Framingham risk HIV patients. European Journal of Clinical Investigation, 2017, 47, 591-599.	3.4	15
75	Impact of interferonâ€free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a realâ€life cohort. Journal of Viral Hepatitis, 2018, 25, 699-706.	2.0	15
76	Polyostotic Osteitis in Secondary Syphilis in an HIV-Infected Patient. Sexually Transmitted Diseases, 2013, 40, 645-646.	1.7	14
77	Directly observed therapy for chronic hepatitis C: A randomized clinical trial in the prison setting. GastroenterologÃa Y HepatologÃa, 2014, 37, 443-451.	0.5	14
78	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2014, 32, 447-458.	0.5	14
79	Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment. Journal of Infection, 2007, 54, 159-166.	3.3	13
80	Prevalence of HLA-B*5701 in HIV-Infected Patients in Spain (Results of the EPI Study). HIV Clinical Trials, 2009, 10, 48-51.	2.0	13
81	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. Journal of Antimicrobial Chemotherapy, 2021, 76, 2380-2393.	3.0	13
82	Is Visceral Leishmaniasis Different in Immunocompromised Patients Without Human Immunodeficiency Virus? A Comparative, Multicenter Retrospective Cohort Analysis. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1127-1133.	1.4	13
83	Impact of vitamin <scp>D</scp> insufficiency on insulin homeostasis and beta cell function in nondiabetic male <scp>HIV</scp> â€infected patients. HIV Medicine, 2013, 14, 540-548.	2.2	12
84	Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 517-523.	0.5	12
85	The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. Journal of Antimicrobial Chemotherapy, 2020, 75, 1294-1300.	3.0	12
86	Impact of Advanced HIV Disease on Quality of Life and Mortality in the Era of Combined Antiretroviral Treatment. Journal of Clinical Medicine, 2021, 10, 716.	2.4	12
87	Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates. European Journal of Clinical Microbiology and Infectious Diseases, 2006, 25, 695-701.	2.9	11
88	Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. Journal of Antimicrobial Chemotherapy, 2013, 68, 1373-1381.	3.0	11
89	Prevalence of <i>Trypanosoma cruzi</i> infection in Latin American pregnant women and level of compliance of the Valencian Health Programme in the city of Alicante. Epidemiology and Infection, 2014, 142, 888-890.	2.1	11
90	Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007–2012). Clinical Microbiology and Infection, 2015, 21, 105.e1-105.e5.	6.0	11

#	Article	IF	CITATIONS
91	Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 516.e1-516.e18.	0.5	11
92	La formación de grado en enfermedades infecciosas, resistencia y uso de antibióticos desde la perspectiva de los estudiantes de Medicina. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 25-30.	0.5	11
93	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 544-556.	0.5	10
94	Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, e36-e44.	2.1	10
95	Clinical presentation of HIV infection in patients aged 50 years or older. Journal of Infection, 1998, 37, 213-216.	3.3	9
96	Usefulness of pp65 Antigenemia for the Early Diagnosis of Cytomegalovirus Disease in Patients with AIDS. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 630-635.	2.9	9
97	Angiolipomas, a rare manifestation of HIV-associated lipodystrophy. Aids, 2008, 22, 552-554.	2.2	9
98	Current Prevalence and Characteristics of Dermatoses Associated with Human Immunodeficiency Virus Infection. Actas Dermo-sifiliográficas, 2010, 101, 702-709.	0.4	9
99	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 195-202.	0.5	9
100	Nosocomial Outbreak of Scabies Clinically Resistant to Lindane. Infection Control and Hospital Epidemiology, 1997, 18, 677-677.	1.8	9
101	Drug Toxicity or Syndrome of Immune Restoration Causing Fulminant Cirrhosis After HAART-Induced Immune Recovery. European Journal of Clinical Microbiology and Infectious Diseases, 2002, 21, 153-155.	2.9	8
102	Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. Clinical Microbiology and Infection, 2017, 23, 409.e5-409.e8.	6.0	8
103	Consensus document on the management of renal disease in HIV-infected patients. Nefrologia, 2014, 34 Suppl 2, 1-81.	0.4	8
104	Fournier's Gangrene in HIV-Infected Patients. European Journal of Clinical Microbiology and Infectious Diseases, 2001, 20, 910-913.	2.9	7
105	Host and disease factors are associated with cognitive function in European <scp>HIV</scp> â€infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 2016, 17, 471-478.	2.2	7
106	Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens. Frontiers in Immunology, 2022, 13, 848630.	4.8	7
107	Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. Journal of Antimicrobial Chemotherapy, 2009, 64, 398-410.	3.0	6
108	Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases, 2015, 60, 1262-1268.	5.8	6

#	Article	IF	CITATIONS
109	Palliative Sedation in COVID-19 End-of-Life Care. Retrospective Cohort Study. Medicina (Lithuania), 2021, 57, 873.	2.0	6
110	Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy. International Journal of STD and AIDS, 2005, 16, 807-810.	1.1	5
111	Measles in adults during an outbreak in Spain: hospitalization associated with gastrointestinal and liver involvement. Infection, 2014, 42, 763-765.	4.7	5
112	Biological markers of fertility (inhibinâ€B) in <scp>HIV</scp> â€infected men: influence of <scp>HIV</scp> infection and antiretroviral therapy. HIV Medicine, 2016, 17, 436-444.	2.2	5
113	Empirical monotherapy with meropenem or combination therapy: the microbiological point of view. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 1851-1855.	2.9	5
114	Impact of circulating bacterial DNA in long-term glucose homeostasis in non-diabetic patients with HIV infection: cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 313-318.	2.9	5
115	Tratamiento directamente observado de la infección tuberculosa latente: estudio comparativo de dos pautas con isoniacida. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2003, 21, 293-295.	0.5	5
116	Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004–2018. BMC Infectious Diseases, 2022, 22, 379.	2.9	5
117	Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study. Journal of the International AIDS Society, 2014, 17, 19803.	3.0	4
118	Combined Effect of Sex and Age in Response to Antiretroviral Therapy in HIV-Infected Patients. Antiviral Therapy, 2017, 22, 21-29.	1.0	4
119	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. Journal of Antimicrobial Chemotherapy, 2020, 75, 1955-1960.	3.0	4
120	Origin of hyperamylasaemia in HIV-infected patients. Aids, 1996, 10, 553-55.	2.2	3
121	Vertebral osteomyelitis and epidural abscess in a patient receiving enfuvirtide. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 580-1.	2.9	3
122	Switching from a Toxicity-Causing Antiretroviral to Enfuvirtide in Patients with HIV: The SWITCH TOX Study. HIV Clinical Trials, 2008, 9, 375-386.	2.0	3
123	Safety, Efficacy, and Persistence of Emtricitabine/Tenofovir Versus Other Nucleoside Analogues in Naive Subjects Aged 50 Years or Older in Spain: The TRIP Study. HIV Clinical Trials, 2013, 14, 204-215.	2.0	3
124	Malestar emocional de pacientes y familiares en la Unidad de Cuidados Paliativos de un hospital general: un estudio piloto. Medicina Paliativa, 2018, 25, 191-194.	0.0	3
125	Role of HIV in the desire of procreation and motherhood in women living with HIV in Spain: a qualitative approach. BMC Women's Health, 2018, 18, 24.	2.0	3
126	Highly active antiretroviral therapy for patients with tuberculosis: the solution or the problem?. Aids, 2002, 16, 1436-1437.	2.2	3

#	Article	IF	CITATIONS
127	Can alprostadil improve liver failure in HIV-infected patients with severe acute viral hepatitis?. Journal of Infection, 1998, 37, 84-86.	3.3	2
128	Cytomegalovirus Polyradiculopathy Presenting as Bilateral Radial Nerve Palsies in a Patient with AIDS. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 605-606.	2.9	2
129	Isolation of Candida auris in large hospitals in the Autonomous Community of Valencia; population-based study (2013–2017). Revista Iberoamericana De Micologia, 2021, 38, 141-144.	0.9	2
130	Latin American Origin Is Not Associated with Worse Outcomes among Hospitalized Patients with COVID-19 in a Public Healthcare System. Microorganisms, 2021, 9, 1772.	3.6	2
131	Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study. Current HIV Research, 2012, 10, 673-678.	0.5	2
132	Update on bacterial infections in immunosuppressed patients. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2007, 25, 12-18.	0.5	1
133	Cutaneous Drug Reactions in HIV-Infected Patients in the HAART Era. Actas Dermo-sifiliogrÃįficas, 2009, 100, 253-265.	0.4	1
134	Inflammation and microbial translocation in treatment-controlled HIV patients. Antiviral Therapy, 2013, 18, 837-840.	1.0	1
135	Genotypic tropism testing of proviral <scp>DNA</scp> to guide maraviroc initiation in aviraemic subjects: 48â€week analysis of results from the <scp>PROTEST</scp> study. HIV Medicine, 2017, 18, 482-489.	2.2	1
136	The Role of Mental Health Conditions in the Diagnosis of Neurocognitive Impairment in People Living with HIV. Diagnostics, 2020, 10, 543.	2.6	1
137	Predictores de progresión y muerte en pacientes con infección avanzada por el VIH en la era de los tratamientos antirretrovirales de gran actividad. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2004, 22, 142-149.	0.5	1
138	Executive summary of the consensus document on the management of renal disease in HIV-infected patients. Nefrologia, 2014, 34, 768-88.	0.4	1
139	Enfermedades infecciosas en pacientes hospitalizados de más de 89 años de edad. Revista Clinica Espanola, 2013, 213, 316-318.	0.6	0
140	Inflammatory biomarkers in the pathogenesis of respiratory dysfunction in people living with HIV. Current HIV Research, 2021, 19, .	0.5	0
141	Inflammation and microbial translocation in treatment-controlled HIV patients. Antiviral Therapy, 2013, 18, 837-840.	1.0	0
142	Ceftazidima en infusiÃ <sup>3</sup> n continua en el tratamiento de infecciones por Pseudomonas aeruginosa en una Unidad de HospitalizaciÃ <sup>3</sup> n a Domicilio. Enfermedades Infecciosas Y MicrobiologÃa ClÂnica, 2007, 25, 71-72.	0.5	0